Recommended Dose Estimation of BP-C2
NCT04186585
Summary
The aim is to estimate an oral administered recommended dose of BP-C2 in addition to hormone treatment of prostate cancer. The study population consists of prostatic cancer patients between 18 and 80 years of age undergoing hormonal treatment. Four patients will be recruited consecutively from each of two participating hospital. The study will be performed as an open, one-dimensional multi-center trial with a 3-level within-patient Response Surface Pathway (RSP) design.
Eligibility
Inclusion Criteria: * Prostate cancer patients between 18 and 80 years of age under hormonal treatment Exclusion Criteria: * Patients with expected survival time below 3 months * Abnormal liver function classified as total bilirubin \>34 µmol/l or ALAT \> 3 times the upper normal range (ULN). In case of metastases in the liver, the ALAT limit for exclusion is set to 5 x ULN. * Abnormal kidney function defined by serum creatinine \>120 µmol/l. * Patients with verified metastasis to the brain. * Synchronous cancer except for non-melanoma skin cancer and early stage of cervical cancer. * Clinically significant abnormal ECG. * Under radiological therapy * Under systemic treatment with corticosteroids or other immunosuppressive drugs the last 3 weeks before start of the trial treatment. * Participating in another clinical trial with pharmaceuticals the last six weeks before start of this trial treatment. * Not able to understand information. * Do not want or not able to give written consent to participate in the study.
Conditions2
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT04186585